Assembly Biosciences (FRA:V7B) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:V7B Assembly Biosciences Inc FRA:V7B
37 GF Score
Price €21.85
GF Value €17.56
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Assembly Biosciences Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:V7B
37GF Score
Assembly Biosciences Inc FRA:V7B
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Assembly Biosciences (FRA:V7B) Overvalued in 2026?

Based on GuruFocus' analysis, Assembly Biosciences stock appears to be overvalued. The current stock price of €21.85 is trading 24.4% above its estimated GF Value™ of €17.56. GuruFocus considers Assembly Biosciences to be Modestly Overvalued.

Key valuation signals for FRA:V7B:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €17.56 vs. price of €21.85 (24.4% above fair value)
  • GF Score™: 37/100 with 3 warning signs

No single metric tells the full story. See the FRA:V7B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Assembly Biosciences Business Description

Other Exchanges ASMB:USAV7B:Germany
Address Two Tower Place, 7th Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
37GF Score

Get the complete analysis for FRA:V7B

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.85
Price
€17.56
GF Value